首页> 外文会议>International conference on applied biotechnology >Research Progress on the Anti-Rheumatoid Arthritis Drugs
【24h】

Research Progress on the Anti-Rheumatoid Arthritis Drugs

机译:抗风湿性关节炎药物的研究进展

获取原文

摘要

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease leading to synovial hyperplasia and a series of multisystem comorbidities. Permanent disability usually occurs in 20-30 % of untreated patients within 2-3 years of the disease. Therefore, it is important to diagnose the disease and initiate treatment as early as possible. The drug therapy plays an important role in maintaining a state of very low disease activity and slowing the progression of joint damage. Traditional drug therapy in RA is a pyramid approach, in which nonsteroidal anti-inflammatory drugs (NSAIDs) serve as the base of pyramid and disease-modifying antirheumatic drugs (DMARDs) are employed relatively late. But since this approach is no longer valid, many new drugs used to manage RA have been developed. In this review, we specifically summarize the current drug therapies for the treatment of RA and briefly describe the etiology, pathology and pathogenesis of RA.
机译:类风湿关节炎(RA)是导致滑膜增生和一系列多系统合并症的慢性全身性自身免疫性疾病。永久性残疾通常在疾病的2-3年内发生在20-30%的未经治疗的患者中。因此,重要的是尽早诊断疾病并开始治疗。药物疗法在维持极低的疾病活动状态和减慢关节损伤进展中起着重要作用。 RA中的传统药物疗法是一种金字塔方法,其中非甾体类抗炎药(NSAID)用作金字塔的基础,而疾病缓解性抗风湿药(DMARD)的使用相对较晚。但是由于这种方法不再有效,因此已经开发出许多用于治疗RA的新药。在这篇综述中,我们专门总结了目前用于治疗RA的药物疗法,并简要介绍了RA的病因,病理和发病机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号